<?xml version='1.0' encoding='utf-8'?>
<document id="25505887"><sentence text="Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe."><entity charOffset="87-99" id="DDI-PubMed.25505887.s1.e0" text="atorvastatin" /><entity charOffset="104-113" id="DDI-PubMed.25505887.s1.e1" text="ezetimibe" /><pair ddi="false" e1="DDI-PubMed.25505887.s1.e0" e2="DDI-PubMed.25505887.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25505887.s1.e0" e2="DDI-PubMed.25505887.s1.e1" /></sentence><sentence text="Recent clinical research has shown that atorvastatin (ATO) in combination with cholesterol absorption inhibitor ezetimibe (EZE) significantly reduces LDL-C level in patients with hypercholesterolemia, showing a superior lipid-lowering efficacy compared to statin alone"><entity charOffset="40-52" id="DDI-PubMed.25505887.s2.e0" text="atorvastatin" /><entity charOffset="54-57" id="DDI-PubMed.25505887.s2.e1" text="ATO" /><entity charOffset="79-90" id="DDI-PubMed.25505887.s2.e2" text="cholesterol" /><entity charOffset="112-121" id="DDI-PubMed.25505887.s2.e3" text="ezetimibe" /><entity charOffset="123-126" id="DDI-PubMed.25505887.s2.e4" text="EZE" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e0" e2="DDI-PubMed.25505887.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e0" e2="DDI-PubMed.25505887.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e0" e2="DDI-PubMed.25505887.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e0" e2="DDI-PubMed.25505887.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e0" e2="DDI-PubMed.25505887.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e1" e2="DDI-PubMed.25505887.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e1" e2="DDI-PubMed.25505887.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e1" e2="DDI-PubMed.25505887.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e1" e2="DDI-PubMed.25505887.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e2" e2="DDI-PubMed.25505887.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e2" e2="DDI-PubMed.25505887.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e2" e2="DDI-PubMed.25505887.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e3" e2="DDI-PubMed.25505887.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25505887.s2.e3" e2="DDI-PubMed.25505887.s2.e4" /></sentence><sentence text=" With no information currently available on the interaction between the two drugs, a pharmacokinetic study was conducted to investigate the influence of EZE on ATO and conversely when the two drugs were coadministered"><entity charOffset="160-162" id="DDI-PubMed.25505887.s3.e0" text="ATO" /><entity charOffset="153-155" id="DDI-PubMed.25505887.s3.e1" text="EZE" /><pair ddi="false" e1="DDI-PubMed.25505887.s3.e1" e2="DDI-PubMed.25505887.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25505887.s3.e1" e2="DDI-PubMed.25505887.s3.e0" /></sentence><sentence text=" The purpose of this study was to investigate the presence of differences in the pharmacokinetic profiles of capsules containing ATO 80 mg, EZE 10 mg or the combination of both 80/10 mg administered to healthy Mexican volunteers"><entity charOffset="129-131" id="DDI-PubMed.25505887.s4.e0" text="ATO" /><entity charOffset="140-142" id="DDI-PubMed.25505887.s4.e1" text="EZE" /><pair ddi="false" e1="DDI-PubMed.25505887.s4.e0" e2="DDI-PubMed.25505887.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25505887.s4.e0" e2="DDI-PubMed.25505887.s4.e1" /></sentence><sentence text=" This was a randomized, three-period, six-sequences crossover study" /><sentence text=" 36 eligible subjects aged between 20 to 50 years were included" /><sentence text=" Blood samples were collected up to 96 h after dosing, and pharmacokinetic parameters were obtained by non-compartmental analysis" /><sentence text=" Adverse events were evaluated based on subject interviews and physical examinations" /><sentence text=" Area under the concentration-time curve (AUC) and maximum plasma drug concentration (Cmax) were measured for each drug alone or together and tested for bioequivalence-based hypothesis" /><sentence text=" The estimation computed (90% confidence intervals) for AUC and Cmax, were 96" /><sentence text="04% (85" /><sentence text="88-107" /><sentence text="42%) and 97" /><sentence text="04% (82" /><sentence text="36-114" /><sentence text="35%), respectively for ATO-EZE combination versus ATO alone, while 84"><entity charOffset="23-30" id="DDI-PubMed.25505887.s16.e0" text="ATO-EZE" /><entity charOffset="50-56" id="DDI-PubMed.25505887.s16.e1" text="ATO" /><entity charOffset="27-33" id="DDI-PubMed.25505887.s16.e2" text="EZE" /><pair ddi="false" e1="DDI-PubMed.25505887.s16.e0" e2="DDI-PubMed.25505887.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25505887.s16.e0" e2="DDI-PubMed.25505887.s16.e2" /><pair ddi="false" e1="DDI-PubMed.25505887.s16.e0" e2="DDI-PubMed.25505887.s16.e1" /><pair ddi="false" e1="DDI-PubMed.25505887.s16.e2" e2="DDI-PubMed.25505887.s16.e2" /><pair ddi="false" e1="DDI-PubMed.25505887.s16.e2" e2="DDI-PubMed.25505887.s16.e1" /></sentence><sentence text="42% (77" /><sentence text="19-92" /><sentence text="32%) and 95" /><sentence text="60% (82" /><sentence text="43-110" /><sentence text="88%), respectively, for ATO-EZE combination versus EZE alone were estimated"><entity charOffset="24-31" id="DDI-PubMed.25505887.s22.e0" text="ATO-EZE" /><entity charOffset="28-34" id="DDI-PubMed.25505887.s22.e1" text="EZE" /><entity charOffset="51-57" id="DDI-PubMed.25505887.s22.e2" text="EZE" /><pair ddi="false" e1="DDI-PubMed.25505887.s22.e0" e2="DDI-PubMed.25505887.s22.e0" /><pair ddi="false" e1="DDI-PubMed.25505887.s22.e0" e2="DDI-PubMed.25505887.s22.e1" /><pair ddi="false" e1="DDI-PubMed.25505887.s22.e0" e2="DDI-PubMed.25505887.s22.e2" /><pair ddi="false" e1="DDI-PubMed.25505887.s22.e1" e2="DDI-PubMed.25505887.s22.e1" /><pair ddi="false" e1="DDI-PubMed.25505887.s22.e1" e2="DDI-PubMed.25505887.s22.e2" /></sentence><sentence text=" These results suggest that ATO and EZE have no relevant pharmacokinetic drug-drug interaction"><entity charOffset="28-30" id="DDI-PubMed.25505887.s23.e0" text="ATO" /><entity charOffset="36-38" id="DDI-PubMed.25505887.s23.e1" text="EZE" /><pair ddi="false" e1="DDI-PubMed.25505887.s23.e0" e2="DDI-PubMed.25505887.s23.e0" /><pair ddi="false" e1="DDI-PubMed.25505887.s23.e0" e2="DDI-PubMed.25505887.s23.e1" /></sentence><sentence text=" " /></document>